Clinical Trial Update: Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies [Phase 3]

View source ↗

Summary

This Phase 3 trial assesses a reduced dose of post-transplant cyclophosphamide in patients undergoing haploidentical hematopoietic stem cell transplantation for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: GVHD - Graft-Versus-Host Disease, HSCT | Phase 3 | Status: NOT_YET_RECRUITING